Diagnostic Reagent Biotechnology: An Industry Observation from Raw Material Quality Control to Cold Chain Delivery

Raw material quality control: Biotechnology builds the starting point of performance

The performance foundation of in vitro diagnostic reagents lies in core biological raw materials, including recombinant antigens, monoclonal antibodies, tool enzymes, nucleic acid primers and probes, etc. Modern biotechnology, through gene cloning, cell culture, protein engineering, and other means, provides diagnostic reagents with a more stable source of raw materials. In actual production, companies often establish a tiered supplier management system, conducting incoming inspection and sample retention for key raw materials. Common quality control items cover general requirements such as appearance, solubility, activity, purity, and cross-reactivity. The consistency between raw material batches is directly related to the stability of subsequent production processes, so standardized operations and record traceability are needed to reduce quality drift caused by raw material fluctuations. It should be noted that a single raw material parameter cannot fully represent finished product performance and must be comprehensively judged in combination with formulation optimization and process validation.

In the field of molecular diagnostics, the thermal stability and fidelity of tool enzymes such as polymerases and reverse transcriptases have a relatively large impact on amplification results; in immunoassays, antibody affinity and specificity are closely related to detection signals. Biotechnology companies usually conduct functional screening of candidate raw materials in the early stages of research and development and establish a transfer path from small-scale trials and pilot-scale production to scaled-up manufacturing. Only by matching raw material characteristics, process parameters, and intended clinical use can a reliable foundation be laid for subsequent product quality.

Production processes and quality control: From the laboratory to scale-up

When diagnostic reagents move from research and development into production, they need to undergo strict process validation and quality control. Common practices include setting control parameters for key processes such as liquid preparation, dispensing, lyophilization, and assembly, and confirming that products meet established standards through in-process inspection and finished product inspection. Biotechnology methods such as real-time fluorescence quantitative PCR, enzyme-linked immunosorbent assay, and protein electrophoresis can be used for process monitoring and finished product release. The production environment is generally managed according to cleanliness requirements to avoid microbial contamination and cross-interference.

For in vitro diagnostic reagents, quality systems usually refer to good manufacturing practice for medical devices and related standards. Companies need to establish systems for batch production records, equipment calibration, personnel training, deviation handling, and corrective and preventive actions. Especially in multi-product shared-line production, cleaning validation and cross-contamination prevention measures are particularly critical. Although the process complexity of different products varies, full-process documentation, data integrity, and traceability are compliance baselines commonly emphasized by industry regulation.

Cold chain logistics and connection with clinical use

Most diagnostic reagents contain biologically active ingredients and are relatively sensitive to storage and transportation temperatures. Common temperature ranges include frozen, refrigerated, and cool room-temperature conditions, with the specific conditions determined based on product stability study results. Cold chain management generally covers warehousing environment monitoring, validation of refrigerated transport equipment, calibration of temperature recorders, and acceptance upon arrival. If a temperature deviation occurs during transportation, the receiving party should evaluate the impact on product performance according to deviation handling procedures rather than directly releasing it for use.

In medical institutions or third-party laboratories, reagent storage, reconstitution, calibration, and quality control also affect test results. Biotechnology companies usually provide accompanying instructions, calibrators, or quality control materials and provide necessary training for users. By connecting the information chain among production, logistics, and end use, it helps reduce testing deviations caused by improper storage or operational errors and improves overall diagnostic reliability.

Regulatory compliance and industry trends

In China, in vitro diagnostic reagents are managed as medical devices, and different risk levels correspond to different registration or filing pathways. Before a product is marketed, materials such as performance evaluation, stability studies, and clinical evaluation generally need to be completed, and after marketing, adverse event monitoring and quality system inspections are also required. The rapid progress of biotechnology, such as iterative advances in digital PCR, microfluidics, and chemiluminescence, is driving diagnostic reagents toward automation, high throughput, and combined multi-indicator detection.

Under the compliance framework, companies need to continuously monitor standard updates and regulatory developments and transform biotechnology advantages into verifiable product performance and quality assurance. The focus of industry competition is gradually shifting from comparison of single indicators to comprehensive capabilities in full-process quality, supply chain resilience, and after-sales technical support. For practitioners, understanding the internal connection between biotechnology and the quality logic of diagnostic reagents is a prerequisite for grasping industry opportunities.